Share on StockTwits

Stifel upped their target price on shares of Salix Pharmaceuticals (NASDAQ:SLXP) from $120.00 to $130.00 in a research note issued on Friday. The firm currently has a “buy” rating on the stock. Stifel’s target price points to a potential upside of 14.24% from the stock’s previous close.

SLXP has been the subject of a number of other recent research reports. Analysts at Wells Fargo & Co. initiated coverage on shares of Salix Pharmaceuticals in a research note on Tuesday. They set a “market perform” rating and a $130.00 price target on the stock. Separately, analysts at Zacks downgraded shares of Salix Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Thursday, May 29th. They now have a $122.00 price target on the stock. Finally, analysts at Sterne Agee raised their price target on shares of Salix Pharmaceuticals from $126.00 to $130.00 in a research note on Tuesday, May 27th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. Salix Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $117.04.

Salix Pharmaceuticals (NASDAQ:SLXP) opened at 113.80 on Friday. Salix Pharmaceuticals has a 52 week low of $63.83 and a 52 week high of $120.00. The stock’s 50-day moving average is $110.5 and its 200-day moving average is $101.. The company has a market cap of $7.216 billion and a price-to-earnings ratio of 96.69.

Salix Pharmaceuticals (NASDAQ:SLXP) last posted its quarterly earnings results on Thursday, May 8th. The company reported $1.05 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.91 by $0.14. The company had revenue of $384.00 million for the quarter, compared to the consensus estimate of $372.91 million. During the same quarter in the prior year, the company posted $0.63 earnings per share. The company’s quarterly revenue was up 89.7% on a year-over-year basis. On average, analysts predict that Salix Pharmaceuticals will post $6.49 earnings per share for the current fiscal year.

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.